Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Filings indexed 782 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2026-05-26 English
FORM 8-K
Regulatory Filings
2026-05-22 English
FORM 8-K
Regulatory Filings
2026-05-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
Regulatory Filings
2026-05-13 English
8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
Regulatory Filings
2026-05-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.